Trinity Biotech (TRIB) Earnings Analysis

Trinity Biotech (TRIB) next reports earnings on 2026-09-03, consensus EPS -0.26 USD. Last quarter (2026-04-30) it missed with EPS -0.9 USD vs -0.32 USD est (-181.3%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -0.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TRIB next report earnings?

Next earnings date2026-09-03
Consensus EPS estimate-0.26 USD
Revenue estimate0.01B

TRIB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-30-0.9 USD-0.32 USD-181.3%Miss
2025-12-23-0.32 USD-0.37 USD+13.5%Beat
2025-07-01-2.4 USD-0.51 USD-370.6%Miss
2025-05-15-5.1 USD-0.28 USD-1721.4%Miss
2025-04-03-1.23549 USD-0.3 USD-311.8%Miss
2024-11-15-0.45816 USD-0.54 USD+15.2%Beat

Beat rate: 2/6 (33%) over reported quarters with consensus data.

TRIB valuation and analyst view

Trailing P/E-0.15
Trailing EPS-2.00913 USD
Price / book-0.08
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (3 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Trinity Biotech (TRIB)'s next earnings date?

Trinity Biotech is next scheduled to report on 2026-09-03, with a consensus EPS estimate of -0.26 USD and revenue estimate of 0.01B.

Did TRIB beat earnings last quarter?

In its 2026-04-30 report, TRIB posted EPS of -0.9 USD versus a -0.32 USD estimate — a miss of 181.3%.

What is TRIB's earnings track record?

Over the last 6 reported quarters with consensus data, TRIB beat estimates 2 times (33%).

What is TRIB's current P/E ratio and EPS?

TRIB trades at a trailing P/E of -0.15 on trailing EPS of -2.0091293476170704 USD.

What do analysts rate TRIB?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell).